Vaccination by Leukemic Apoptotic Corpse Autologous Pulsed Dendritic Cells for Acute Myelogenous Leukemia (AML) Patients in First or Second Complete Remission (CR)(CD laM)

Inclusion Criteria: * Age ≥ 60 years * Informed consent signed * Serology HIV, hepatitis B, hepatitis C, HTLV 1 and 2 and Syphilis always negative (new achievement tests) * Performance Statute \<=2 * Must not be eligible for allogeneic transplantation * No progressive disease * Bone marrow and/or peripheral blasts \>50% before chemotherapyBlasts \>=2.4 10\*8 (collected prior to chemotherapy) available No contraindication to cytapheresis * AML in CR2, except M3-AML * Patients with refractory AML after induction treatment and a patient eligible for salvage treatment may allow the production of a first complete remission. * Patient with newly diagnosed AML with unfavorable cytogenetics and for whom (which) a course of intensive induction and consolidation treatment for outpatients are possible * Patient with newly diagnosed AML with a non-adverse cytogenetics AND either refused to participate in the protocol GOELAMS LAMS-2007, against the exclusion criteria, indicating participation in the protocol GOELAMS LAMS-2007 and for whom (which) a course of induction and intensive out patient treatment for consolidation are possible * Absence of donor HLA-compatible family or non-family and absence of placental blood available for performing an allograft. Exclusion Criteria * Patients who, for reasons psychological, social or geographical boundaries, could be monitored during the study * No infections or visceral (cardiac, lung, brain, ...) serious uncontrolled * History of positive allogeneic bone marrow or solid organ transplantation. * Previous history of autoimmune disease other than vitiligo * History of other cancer, except cervical carcinoma in situ or basal cell carcinoma of the skin unless deemed cured for over 5 years. * Inability to collect at the diagnosis of relapsed AML, enough leukemic cells (\> 2.4 x108) * Inability to collect during remission, a sufficient number of monocytes in two leukapheresis maximum * Failure to obtain a maturation of monocytes * Patient with AML 3 * Patient may receive an allogeneic hematopoietic stem cell * No treatment related to treatment of molecules in preclinical development underway or completed MA within the last 4 weeks